Are Allogenic CAR-T cells safe from the Big Pharma rush?

Secondary T-cell carcinoma development reported with CAR-T cells against B-cell carcinoma. This has emerged as a potential barrier to the development of other CAR-T cells and the expansion of CAR-T cell indications such as autoimmune diseases.
https://miyata-bio.net/column/0000316/